Literature DB >> 8418089

Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.

T A Wiklund1, C P Blomqvist, L Risteli, J Risteli, I Elomaa.   

Abstract

We have previously shown that the serum aminoterminal propeptide of type III procollagen (PIIINP) is a prognostic factor for survival in localised soft-tissue sarcomas, and that elevated values are frequent in metastatic disease. In the present study PIINP is analysed during chemotherapy in 26 patients with advanced sarcomas. Non-responders had a significantly higher pretreatment level of PIIINP than responders (P = 0.05), when only patients with no recent therapeutic interventions were studied. However, during chemotherapy PIIINP followed the clinical course of the malignant disease in only a minority of patients. Patients with recent surgery or recently completed chemotherapy had an increased pretreatment PIIINP value (P = 0.03). In these patients PIIINP declined during chemotherapy irrespective of tumour response. A pretreatment PIIINP level within the reference range tended to increase with time irrespective of response. Moreover, the values taken during a chemotherapy infusion were significantly higher than those immediately preceding the corresponding cycle (P = 0.001). Our results suggest that pretreatment PIIINP is of value as a prognostic factor for chemotherapy response in patients with advanced sarcomas. During chemotherapy PIIINP is of minor importance in monitoring response because of the influence of chemotherapy and other therapeutic interventions on the level of PIIINP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418089     DOI: 10.1007/bf01229531

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

Review 1.  Sarcomas of soft tissue and bone.

Authors:  R Mazanet; K H Antman
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

2.  Aminoterminal propeptide of type-III procollagen in serum--an indicator of clinical behavior of advanced ovarian carcinoma?

Authors:  L Risteli; A Kauppila; U M Mäkilä; J Risteli
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

3.  The biosynthesis of collagen and its disorders (first of two parts).

Authors:  D J Prockop; K I Kivirikko; L Tuderman; N A Guzman
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

4.  Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.

Authors:  C Tomás; J Penttinen; J Risteli; L Risteli; J Vuori; A Kauppila
Journal:  Cancer       Date:  1990-12-01       Impact factor: 6.860

5.  Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.

Authors:  J Risteli; S Niemi; P Trivedi; O Mäentausta; A P Mowat; L Risteli
Journal:  Clin Chem       Date:  1988-04       Impact factor: 8.327

6.  Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.

Authors:  T A Wiklund; C P Blomqvist; M Virolainen; I Elomaa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Change in energy and protein status during chemotherapy in patients with acute leukemia.

Authors:  E Lerebours; H Tilly; A Rimbert; J Delarue; H Piguet; R Colin
Journal:  Cancer       Date:  1988-06-15       Impact factor: 6.860

8.  Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings.

Authors:  K Haukipuro; L Risteli; M I Kairaluoma; J Risteli
Journal:  Surgery       Date:  1990-04       Impact factor: 3.982

9.  Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma.

Authors:  C Tomás; J Penttinen; J Risteli; L Risteli; A Kauppila
Journal:  Ann Med       Date:  1990-04       Impact factor: 4.709

10.  Type III collagen metabolism in soft tissue sarcomas.

Authors:  T A Wiklund; I Elomaa; C P Blomqvist; L Risteli; J Risteli
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more
  3 in total

1.  Type I and type III collagen metabolites in adult osteosarcoma patients.

Authors:  T Wiklund; C Blomqvist; L Risteli; J Risteli; E Karaharju; I Elomaa
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

2.  Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

Authors:  C Blomqvist; L Risteli; J Risteli; P Virkkunen; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

3.  Serum levels of laminin, type IV collagen and type III procollagen peptide as markers for detection of metastasis.

Authors:  K Yudoh; H Matsui; M Kanamori; K Ohmori; H Tsuji; S Tatezaki
Journal:  Jpn J Cancer Res       Date:  1994-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.